News

Article

Cytiva Acquires Chromatography Resins Manufacturing Facility in Muskegon, Michigan

Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.

Cytiva announced on July 13, 2022 that it had acquired a new manufacturing facility in Muskegon, MI. The new facility, a chromatography resins manufacturing site, is part of Cytiva and Pall Corporation's $1.5 billion capacity expansion investment, allowing Cytiva to expand its resin manufacturing beyond Sweden.

According to a company press release, Cytiva plans to renovate the site into a 168,000 ft² biomanufacturing center consisting of multiple buildings; it will house approximately 200 associates upon completion. With a planned construction start date in Q3 2022, manufacturing is expected to begin in 2026.

“When you’re looking to help provide global biotechnology solutions to the world, it requires you to be nimble and flexible,” said Emmanuel Ligner, Danaher Group Executive, president and CEO, Cytiva, in the press release. “By investing in Muskegon, Michigan, we will be closer to our North American customers, who are developing advanced biotherapeutics.”

Source: Cytiva

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content